Impact of early relapse after auto-SCT for multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of early relapse after auto-SCT for multiple myeloma

Published:2008-06-30 Issue:6 Volume:42 Page:413-420
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Kumar S,Mahmood S T,Lacy M Q,Dispenzieri A,Hayman S R,Buadi F K,Dingli D,Rajkumar S V,Litzow M R,Gertz M A

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2008180.pdf

Reference41 articles.

1. Bataille R, Harousseau JL . Multiple myeloma. N Engl J Med 1997; 336: 1657–1664.

2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–130.

3. Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382–389.

4. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group. J Clin Oncol 1998; 16: 3832–3842.

5. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of clinical‐biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation;eJHaem;2024-06-16

2. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis;Transplantation and Cellular Therapy;2023-11

3. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma;Cancer;2023-10-17

4. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling;Frontiers in Oncology;2023-10-02

5. Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation;Transplantation and Cellular Therapy;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3